vortioxetine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
serotonin and/or norepinephrine reuptake inhibitors, fluoxetine derivatives	4806	508233-74-7

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: vortioxetine-DL-lactate vortioxetine DL-lactate brintellix Lu AA21004 vortioxetine vortioxetine hydrobromide	A piperazine derivative that acts as a serotonin reuptake inhibitor, as a 5-HT3 receptor antagonist, and 5-HT1A receptor agonist. It is used for the treatment of anxiety and depression. Molecular weight: 298.45 Formula: C18H22N2S CLOGP: 4.92 LIPINSKI: 0 HAC: 2 HDO: 1 TPSA: 15.27 ALOGS: -4.92 ROTB: 3 Status: ONP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

vortioxetine-DL-lactate
vortioxetine DL-lactate
brintellix
Lu AA21004
vortioxetine
vortioxetine hydrobromide

A piperazine derivative that acts as a serotonin reuptake inhibitor, as a 5-HT3 receptor antagonist, and 5-HT1A receptor agonist. It is used for the treatment of anxiety and depression.

Molecular weight: 298.45
Formula: C18H22N2S
CLOGP: 4.92
LIPINSKI: 0
HAC: 2
HDO: 1
TPSA: 15.27
ALOGS: -4.92
ROTB: 3

Status: ONP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
10	mg	O

ADMET properties:

Property	Value	Reference
Vd (Volume of distribution)	35.30 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	5.80 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.02 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	72 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Sept. 30, 2013	FDA	TAKEDA PHARMS USA
Sept. 20, 2019	PMDA	Takeda Pharmaceutical Company Limited

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Nausea	929.88	39.67	397	2017	111792	2243879
Pruritus	562.09	39.67	214	2200	43126	2312545
Suicidal ideation	536.02	39.67	149	2265	10938	2344733
Vomiting	277.18	39.67	153	2261	71449	2284222
Anxiety	180.36	39.67	86	2328	29273	2326398
Depression	150.42	39.67	75	2339	28057	2327614
Rash	147.81	39.67	96	2318	59462	2296209
Feeling abnormal	138.32	39.67	67	2347	23514	2332157
Headache	137.55	39.67	103	2311	80076	2275595
Mania	136.67	39.67	37	2377	2403	2353268
Anger	131.02	39.67	36	2378	2471	2353200
Suicide attempt	124.42	39.67	50	2364	11232	2344439
Insomnia	115.28	39.67	61	2353	25726	2329945
Agitation	111.64	39.67	46	2368	11005	2344666
Dizziness	106.24	39.67	78	2336	58587	2297084
Serotonin syndrome	106.00	39.67	33	2381	3507	2352164
Irritability	105.12	39.67	38	2376	6389	2349282
Tremor	101.23	39.67	52	2362	20609	2335062
Constipation	96.13	39.67	51	2363	21578	2334093
No adverse event	93.96	39.67	39	2375	9489	2346182
Weight increased	91.80	39.67	50	2364	22287	2333384
Completed suicide	91.79	39.67	49	2365	20985	2334686
Abnormal dreams	82.41	39.67	25	2389	2433	2353238
Crying	79.44	39.67	28	2386	4368	2351303
Intentional overdose	77.98	39.67	36	2378	11285	2344386
Somnolence	76.05	39.67	45	2369	23440	2332231
Hyponatraemia	75.37	39.67	37	2377	13288	2342383
Nightmare	72.38	39.67	25	2389	3672	2351999
Wrong technique in product usage process	64.32	39.67	38	2376	19710	2335961
Diarrhoea	63.58	39.67	68	2346	83496	2272175
Vision blurred	60.64	39.67	33	2381	14635	2341036
Contusion	59.08	39.67	31	2383	12779	2342892
Drug ineffective	52.77	39.67	68	2346	101556	2254115
Urticaria	52.34	39.67	36	2378	24225	2331446
Energy increased	50.50	39.67	12	2402	457	2355214
Sexual dysfunction	49.11	39.67	11	2403	321	2355350
Off label use	47.47	39.67	55	2359	73543	2282128
Palpitations	46.68	39.67	29	2385	16427	2339244
Fatigue	45.90	39.67	58	2356	84815	2270856
Blood pressure increased	45.84	39.67	29	2385	16957	2338714
Hyperhidrosis	45.84	39.67	28	2386	15394	2340277
Product use in unapproved indication	45.72	39.67	25	2389	11175	2344496
Electrocardiogram QT prolonged	45.04	39.67	22	2392	7792	2347879
Vertigo	44.07	39.67	23	2391	9361	2346310
Drug abuse	44.05	39.67	25	2389	12001	2343670
Antipsychotic drug level above therapeutic	43.53	39.67	9	2405	178	2355493
Aggression	41.82	39.67	18	2396	4768	2350903
Overdose	41.64	39.67	29	2385	19878	2335793
Sopor	41.52	39.67	17	2397	3978	2351693

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Suicidal ideation	296.33	39.21	83	1013	8435	1737250
Completed suicide	267.09	39.21	89	1007	16223	1729462
Nausea	195.08	39.21	98	998	51098	1694587
Anxiety	159.02	39.21	60	1036	15467	1730218
Sexual dysfunction	101.96	39.21	26	1070	1797	1743888
Vomiting	101.65	39.21	58	1038	38257	1707428
Feeling abnormal	88.70	39.21	36	1060	11130	1734555
Suicide attempt	73.31	39.21	28	1068	7353	1738332
Drug ineffective	72.46	39.21	57	1039	63744	1681941
Agitation	65.67	39.21	29	1067	10997	1734688
Mania	61.17	39.21	18	1078	2115	1743570
Dizziness	60.12	39.21	40	1056	34321	1711364
Headache	57.69	39.21	39	1057	34337	1711348
Depression	57.10	39.21	30	1066	16639	1729046
Intentional overdose	51.58	39.21	22	1074	7648	1738037
Erectile dysfunction	44.37	39.21	17	1079	4480	1741205
Serotonin syndrome	44.31	39.21	15	1081	2773	1742912
Insomnia	41.15	39.21	24	1072	16252	1729433
Weight increased	40.43	39.21	21	1075	11336	1734349

Pharmacologic Action:

Source	Code	Description
ATC	N06AX26	NERVOUS SYSTEM PSYCHOANALEPTICS ANTIDEPRESSANTS Other antidepressants
CHEBI has role	CHEBI:35469	antidepressant
CHEBI has role	CHEBI:35474	anxiolytic drug
CHEBI has role	CHEBI:35941	serotonergic agonist
CHEBI has role	CHEBI:48279	serotonergic antagonist
MeSH PA	D014151	Anti-Anxiety Agents
MeSH PA	D000928	Antidepressive Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D049990	Membrane Transport Modulators
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D014179	Neurotransmitter Uptake Inhibitors
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D058825	Serotonin 5-HT1 Receptor Agonists
MeSH PA	D058831	Serotonin 5-HT3 Receptor Antagonists
MeSH PA	D018490	Serotonin Agents
MeSH PA	D012702	Serotonin Antagonists
MeSH PA	D017366	Serotonin Receptor Agonists
MeSH PA	D017367	Serotonin Uptake Inhibitors
MeSH PA	D014149	Tranquilizing Agents

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Major depressive disorder	indication	370143000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.02	Basic
pKa2	1.85	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 10MG BASE	TRINTELLIX	TAKEDA PHARMS USA	N204447	Sept. 30, 2013	RX	TABLET	ORAL	8476279	Oct. 2, 2022	METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION
EQ 15MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	TRINTELLIX	TAKEDA PHARMS USA	N204447	Sept. 30, 2013	DISCN	TABLET	ORAL	8476279	Oct. 2, 2022	METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION
EQ 20MG BASE	TRINTELLIX	TAKEDA PHARMS USA	N204447	Sept. 30, 2013	RX	TABLET	ORAL	8476279	Oct. 2, 2022	METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION
EQ 5MG BASE	TRINTELLIX	TAKEDA PHARMS USA	N204447	Sept. 30, 2013	RX	TABLET	ORAL	8476279	Oct. 2, 2022	METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION
EQ 10MG BASE	TRINTELLIX	TAKEDA PHARMS USA	N204447	Sept. 30, 2013	RX	TABLET	ORAL	7144884	June 17, 2026	METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION
EQ 15MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	TRINTELLIX	TAKEDA PHARMS USA	N204447	Sept. 30, 2013	DISCN	TABLET	ORAL	7144884	June 17, 2026	METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION
EQ 20MG BASE	TRINTELLIX	TAKEDA PHARMS USA	N204447	Sept. 30, 2013	RX	TABLET	ORAL	7144884	June 17, 2026	METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION
EQ 5MG BASE	TRINTELLIX	TAKEDA PHARMS USA	N204447	Sept. 30, 2013	RX	TABLET	ORAL	7144884	June 17, 2026	METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION
EQ 10MG BASE	TRINTELLIX	TAKEDA PHARMS USA	N204447	Sept. 30, 2013	RX	TABLET	ORAL	8969355	June 15, 2027	METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER
EQ 10MG BASE	TRINTELLIX	TAKEDA PHARMS USA	N204447	Sept. 30, 2013	RX	TABLET	ORAL	9125908	June 15, 2027	USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION
EQ 10MG BASE	TRINTELLIX	TAKEDA PHARMS USA	N204447	Sept. 30, 2013	RX	TABLET	ORAL	9125909	June 15, 2027	USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION
EQ 10MG BASE	TRINTELLIX	TAKEDA PHARMS USA	N204447	Sept. 30, 2013	RX	TABLET	ORAL	9125910	June 15, 2027	USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION
EQ 10MG BASE	TRINTELLIX	TAKEDA PHARMS USA	N204447	Sept. 30, 2013	RX	TABLET	ORAL	9227946	June 15, 2027	METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER
EQ 10MG BASE	TRINTELLIX	TAKEDA PHARMS USA	N204447	Sept. 30, 2013	RX	TABLET	ORAL	9861630	June 15, 2027	METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER
EQ 15MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	TRINTELLIX	TAKEDA PHARMS USA	N204447	Sept. 30, 2013	DISCN	TABLET	ORAL	8969355	June 15, 2027	METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER
EQ 15MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	TRINTELLIX	TAKEDA PHARMS USA	N204447	Sept. 30, 2013	DISCN	TABLET	ORAL	9125908	June 15, 2027	USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION
EQ 15MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	TRINTELLIX	TAKEDA PHARMS USA	N204447	Sept. 30, 2013	DISCN	TABLET	ORAL	9125909	June 15, 2027	USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION
EQ 15MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	TRINTELLIX	TAKEDA PHARMS USA	N204447	Sept. 30, 2013	DISCN	TABLET	ORAL	9125910	June 15, 2027	USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION
EQ 15MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	TRINTELLIX	TAKEDA PHARMS USA	N204447	Sept. 30, 2013	DISCN	TABLET	ORAL	9227946	June 15, 2027	METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER
EQ 15MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	TRINTELLIX	TAKEDA PHARMS USA	N204447	Sept. 30, 2013	DISCN	TABLET	ORAL	9861630	June 15, 2027	METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER
EQ 20MG BASE	TRINTELLIX	TAKEDA PHARMS USA	N204447	Sept. 30, 2013	RX	TABLET	ORAL	8969355	June 15, 2027	METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER
EQ 20MG BASE	TRINTELLIX	TAKEDA PHARMS USA	N204447	Sept. 30, 2013	RX	TABLET	ORAL	9125908	June 15, 2027	USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION
EQ 20MG BASE	TRINTELLIX	TAKEDA PHARMS USA	N204447	Sept. 30, 2013	RX	TABLET	ORAL	9125909	June 15, 2027	USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION
EQ 20MG BASE	TRINTELLIX	TAKEDA PHARMS USA	N204447	Sept. 30, 2013	RX	TABLET	ORAL	9125910	June 15, 2027	USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION
EQ 20MG BASE	TRINTELLIX	TAKEDA PHARMS USA	N204447	Sept. 30, 2013	RX	TABLET	ORAL	9227946	June 15, 2027	METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER
EQ 20MG BASE	TRINTELLIX	TAKEDA PHARMS USA	N204447	Sept. 30, 2013	RX	TABLET	ORAL	9861630	June 15, 2027	METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER
EQ 5MG BASE	TRINTELLIX	TAKEDA PHARMS USA	N204447	Sept. 30, 2013	RX	TABLET	ORAL	8969355	June 15, 2027	METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER
EQ 5MG BASE	TRINTELLIX	TAKEDA PHARMS USA	N204447	Sept. 30, 2013	RX	TABLET	ORAL	9125908	June 15, 2027	USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION
EQ 5MG BASE	TRINTELLIX	TAKEDA PHARMS USA	N204447	Sept. 30, 2013	RX	TABLET	ORAL	9125909	June 15, 2027	USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION
EQ 5MG BASE	TRINTELLIX	TAKEDA PHARMS USA	N204447	Sept. 30, 2013	RX	TABLET	ORAL	9125910	June 15, 2027	USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION
EQ 5MG BASE	TRINTELLIX	TAKEDA PHARMS USA	N204447	Sept. 30, 2013	RX	TABLET	ORAL	9227946	June 15, 2027	METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER
EQ 5MG BASE	TRINTELLIX	TAKEDA PHARMS USA	N204447	Sept. 30, 2013	RX	TABLET	ORAL	9861630	June 15, 2027	METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER
EQ 10MG BASE	TRINTELLIX	TAKEDA PHARMS USA	N204447	Sept. 30, 2013	RX	TABLET	ORAL	9278096	March 21, 2032	USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE TREATMENT EMERGENT SEXUAL DYSFUNCTION (TESD) INDUCED BY PRIOR SEROTONIN REUPTAKE INHIBITOR TREATMENT
EQ 15MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	TRINTELLIX	TAKEDA PHARMS USA	N204447	Sept. 30, 2013	DISCN	TABLET	ORAL	9278096	March 21, 2032	USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE TREATMENT EMERGENT SEXUAL DYSFUNCTION (TESD) INDUCED BY PRIOR SEROTONIN REUPTAKE INHIBITOR TREATMENT
EQ 20MG BASE	TRINTELLIX	TAKEDA PHARMS USA	N204447	Sept. 30, 2013	RX	TABLET	ORAL	9278096	March 21, 2032	USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE TREATMENT EMERGENT SEXUAL DYSFUNCTION (TESD) INDUCED BY PRIOR SEROTONIN REUPTAKE INHIBITOR TREATMENT
EQ 5MG BASE	TRINTELLIX	TAKEDA PHARMS USA	N204447	Sept. 30, 2013	RX	TABLET	ORAL	9278096	March 21, 2032	USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE TREATMENT EMERGENT SEXUAL DYSFUNCTION (TESD) INDUCED BY PRIOR SEROTONIN REUPTAKE INHIBITOR TREATMENT

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
EQ 10MG BASE	TRINTELLIX	TAKEDA PHARMS USA	N204447	Sept. 30, 2013	RX	TABLET	ORAL	May 2, 2021	ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING WITH THE SUBSECTION ENTITLED DIGIT SYMBOL SUBSTITUTION TEST IN MAJOR DEPRESSIVE DISORDER
EQ 15MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	TRINTELLIX	TAKEDA PHARMS USA	N204447	Sept. 30, 2013	DISCN	TABLET	ORAL	May 2, 2021	ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING WITH THE SUBSECTION ENTITLED DIGIT SYMBOL SUBSTITUTION TEST IN MAJOR DEPRESSIVE DISORDER
EQ 20MG BASE	TRINTELLIX	TAKEDA PHARMS USA	N204447	Sept. 30, 2013	RX	TABLET	ORAL	May 2, 2021	ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING WITH THE SUBSECTION ENTITLED DIGIT SYMBOL SUBSTITUTION TEST IN MAJOR DEPRESSIVE DISORDER
EQ 5MG BASE	TRINTELLIX	TAKEDA PHARMS USA	N204447	Sept. 30, 2013	RX	TABLET	ORAL	May 2, 2021	ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING WITH THE SUBSECTION ENTITLED DIGIT SYMBOL SUBSTITUTION TEST IN MAJOR DEPRESSIVE DISORDER
EQ 10MG BASE	TRINTELLIX	TAKEDA PHARMS USA	N204447	Sept. 30, 2013	RX	TABLET	ORAL	Oct. 19, 2021	UPDATE TO THE PRESCRIBING INFORMATION FOR VORTIOXETINE ON TREATMENT-EMERGENT SEXUAL DYSFUNCTION COMPARING VORTIOXETINE AND SSRIS
EQ 15MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	TRINTELLIX	TAKEDA PHARMS USA	N204447	Sept. 30, 2013	DISCN	TABLET	ORAL	Oct. 19, 2021	UPDATE TO THE PRESCRIBING INFORMATION FOR VORTIOXETINE ON TREATMENT-EMERGENT SEXUAL DYSFUNCTION COMPARING VORTIOXETINE AND SSRIS
EQ 20MG BASE	TRINTELLIX	TAKEDA PHARMS USA	N204447	Sept. 30, 2013	RX	TABLET	ORAL	Oct. 19, 2021	UPDATE TO THE PRESCRIBING INFORMATION FOR VORTIOXETINE ON TREATMENT-EMERGENT SEXUAL DYSFUNCTION COMPARING VORTIOXETINE AND SSRIS
EQ 5MG BASE	TRINTELLIX	TAKEDA PHARMS USA	N204447	Sept. 30, 2013	RX	TABLET	ORAL	Oct. 19, 2021	UPDATE TO THE PRESCRIBING INFORMATION FOR VORTIOXETINE ON TREATMENT-EMERGENT SEXUAL DYSFUNCTION COMPARING VORTIOXETINE AND SSRIS

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN	AGONIST	Ki	7.82	SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN	INHIBITOR	Ki	8.80	SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE
5-hydroxytryptamine receptor 7	GPCR	P34969	5HT7R_HUMAN	ANTAGONIST	Ki	7.72	SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE
5-hydroxytryptamine receptor 1D	GPCR	P28221	5HT1D_HUMAN	ANTAGONIST	Ki	7.27	DRUG LABEL	DRUG LABEL
5-hydroxytryptamine receptor 1B	GPCR	P28222	5HT1B_HUMAN	AGONIST	Ki	7.48	SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE
5-hydroxytryptamine receptor 3A	Ion channel	P46098	5HT3A_HUMAN	ANTAGONIST	Ki	8.43	SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE
Histamine H2 receptor	GPCR	P25021	HRH2_HUMAN		Ki	6.74	CHEMBL
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	6.74	CHEMBL
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	6.74	CHEMBL
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN		Ki	6.74	CHEMBL
5-hydroxytryptamine receptor 5A	GPCR	P47898	5HT5A_HUMAN		Ki	6.66	CHEMBL
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	6.48	CHEMBL
Beta-2 adrenergic receptor	GPCR	P07550	ADRB2_HUMAN		Ki	6.25	CHEMBL
Beta-1 adrenergic receptor	GPCR	P08588	ADRB1_HUMAN		Ki	7.34	CHEMBL
Sodium-dependent serotonin transporter	Transporter		SC6A4_RAT		IC50	8.28	CHEMBL
5-hydroxytryptamine receptor 1D	GPCR		5HT1D_RAT	ANTAGONIST	IC50	5.40	IUPHAR
5-hydroxytryptamine receptor 7	GPCR		5HT7R_RAT		Ki	6.70	SCIENTIFIC LITERATURE
Sodium-dependent dopamine transporter	Transporter		SC6A3_RAT		IC50	6.05	CHEMBL
5-hydroxytryptamine receptor 3A	Ion channel		5HT3A_RAT		Ki	6.64	CHEMBL

External reference:

ID	Source
D000078784	MESH_DESCRIPTOR_UI
D10184	KEGG_DRUG
C3667599	UMLSCUI
3O2K1S3WQV	UNII
9279	INN_ID
768282000	SNOMEDCT_US
015226	NDDF
d08125	MMSL
1455099	RXNORM
4032784	VANDF
708717008	SNOMEDCT_US
9966051	PUBCHEM_CID
CHEBI:76016	CHEBI
960203-27-4	SECONDARY_CAS_RN
DB09068	DRUGBANK_ID
CHEMBL2104993	ChEMBL_ID
CHEMBL2107387	ChEMBL_ID
7351	IUPHAR_LIGAND_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Trintellix	HUMAN PRESCRIPTION DRUG LABEL	1	55154-0256	TABLET, FILM COATED	10 mg	ORAL	NDA	21 sections
Trintellix	HUMAN PRESCRIPTION DRUG LABEL	1	55154-0257	TABLET, FILM COATED	20 mg	ORAL	NDA	21 sections
Trintellix	HUMAN PRESCRIPTION DRUG LABEL	1	64764-720	TABLET, FILM COATED	5 mg	ORAL	NDA	21 sections
Trintellix	HUMAN PRESCRIPTION DRUG LABEL	1	64764-730	TABLET, FILM COATED	10 mg	ORAL	NDA	21 sections
Trintellix	HUMAN PRESCRIPTION DRUG LABEL	1	64764-750	TABLET, FILM COATED	20 mg	ORAL	NDA	21 sections